SFCM
IKT icon

Seven Fleet Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Seven Fleet Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$704K Buy
346,900
+21,300
+7% +$38.1K 0.12% 66
2026
Q1 		$547K Sell
325,600
-208,048
-39% -$369K 0.17% 79
2025
Q4 		$1.09M Buy
+533,648
New +$849K 0.74% 25

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Seven Fleet Capital Management's IKT Position: Q2 2026 in Review

Seven Fleet Capital Management increased its Inhibikase Therapeutics (IKT) stake by 6.5% in Q2 2026, buying an estimated $38.1K and bringing the position to 346,900 shares worth $704K. The position accounts for 0.12% of the portfolio, ranked #66.

Seven Fleet Capital Management first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.09M in Q4 2025. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Seven Fleet Capital Management held 346,900 shares of Inhibikase Therapeutics worth $704K as of Q2 2026.
  • Seven Fleet Capital Management bought 21,300 Inhibikase Therapeutics shares in Q2 2026, an estimated $38.1K.
  • Inhibikase Therapeutics made up 0.12% of Seven Fleet Capital Management's portfolio in Q2 2026, its #66 holding.
  • Seven Fleet Capital Management first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Seven Fleet Capital Management's Inhibikase Therapeutics position peaked at $1.09M in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.